PMDA drug package insert
ウステキヌマブBS点滴静注130mg「YD」
PMDA Prescription drug · 陽進堂ホールディングス株式会社 · package insert Aug 25, 2026
Key facts
| Brand names | ウステキヌマブBS点滴静注130mg「YD」 |
|---|---|
| Nonproprietary names | ウステキヌマブ（遺伝子組換え） |
| Companies | 製造販売元（輸入）／陽進堂ホールディングス株式会社 |
| Product type | Prescription drug |
| Therapeutic category | ヒト型抗ヒトIL-12/23p40モノクローナル抗体製剤 |
| Therapeutic category codes | 873999 |
| YJ codes | 39994F4A1027 |
| Approval numbers | 30800AMX00317 |
| Package insert edition | 第1版 |
| Package insert date | Aug 25, 2026 |
| PMDA document key | 830001_39994F4A1027_1 |
| PMDA company code | 830001 |
At a glance
- 1–9 Package insert revisions
- 1–9 Related PMDA documents
- None Safety communications
- No PMDA review report published
- Yes Risk management plan (RMP)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMDA approved drugs and package inserts (Japan)
Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.
Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date: